Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
26 April 2022
13 April 2022
11 April 2022
16 March 2022
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022
BioTrinity, April 2022 (Slides)
IMC Half Year Results, Feb 2022 (Slides)
IMC Full Year Results, Oct 2021 (Slides)
LSX World Congress, Feb 2021 (Video)
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
